Cleave Biosciences' Series A - II Round

Cleave Biosciences raised a round of funding on November 15, 2011. Investors include Osage University Partners.

Cleave Biosciences develops drugs that target protein homeostasis systems and improve the treatment of solid tumors and hematologic malignancies. The company's CB-5083 is an oral inhibitor of p97, a c…

Articles about Cleave Biosciences' Series A - II Round: